A Two-Part, Single-Blind, Phase 3 Study Evaluating the Efficacy and Safety of Patiromer for the Treatment of Hyperkalemia (OPAL)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 243 participants.
Also called NCT01810939
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 243 participants
- Sponsor
- Registry
-
NCT01810939 -
2012-001956-20
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Croatia, Czechia, Denmark, Georgia, Hungary, Italy, Serbia, Slovenia, Ukraine
- Registry status
- Completed
Technical summary
Registry record NCT01810939. Randomized; single masking; primary purpose treatment. Start 2013-02 (registry gives no type); primary completion 2013-07 (actual). Results posted on 2015-12-15.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Two-Part, Single-Blind, Phase 3 Study Evaluating the Efficacy and Safety of Patiromer for the Treatment of Hyperkalemia (OPAL)
- Acronym
- OPAL
- Condition
- Hyperkalemia (HK)
- Intervention (Drug)
- Patiromer
- Intervention (Drug)
- Placebo
- Lead sponsor
- Relypsa, Inc.
Record details
- Record id
cardio:ct-nct01810939- Content hash
2d491d2f1e1e6c2889bd283a66e10f89d4961a17d74a6cc3122b280b8ab0db5a